Evidence map›Paper›PMID 35978276›Full record

ArticleBMC public health2022

Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.

Jens-Ulrich Stegmann, Viviane Jusot, Olga Menang, Gregory Gardiner, Sabino Vesce, Stephanie Volpe, Anderson Ndalama, Felix Adou, Opokua Ofori-Anyinam, Olakunle Oladehin and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 6 countries.

Jens-Ulrich StegmannGSK, Avenue Fleming 20, 1300, Wavre, Belgium.
Viviane JusotGSK, Avenue Fleming 20, 1300, Wavre, Belgium. viviane.x.jusot@gsk.com.ORCID 0000-0002-7747-8788
Olga MenangPATH, Geneva, Switzerland.
Gregory GardinerGSK, London, UK.
Sabino VesceGSK, Nyon, Switzerland.
Stephanie VolpeGSK, Avenue Fleming 20, 1300, Wavre, Belgium.
Anderson NdalamaPharmacy and Medicines Regulatory Authority, Lilongwe, Malawi.
Felix AdouAutorité Ivoirienne de Régulation Pharmaceutique (AIRP), Abidjan, Côte d'Ivoire.
Opokua Ofori-AnyinamGSK, Avenue Fleming 20, 1300, Wavre, Belgium.
Olakunle OladehinGSK, Lagos, Nigeria.
Yolanda Guerra MendozaGSK, Avenue Fleming 20, 1300, Wavre, Belgium.
GlaxoSmithKline (Belgium) · BEEuropean Medicines Agency · NLLagos State Health Service Commission · NGMalawi Government · MWNovartis (Switzerland) · CHSociété de Développement des Forêts · CI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacovigilance (PV) systems in many countries in sub-Saharan Africa (SSA) are not fully functional. The spontaneous adverse events (AE) reporting rate in SSA is lower than in any other region of the world, and healthcare professionals (HCPs) in SSA countries have limited awareness of AE surveillance and reporting procedures. The GSK PV enhancement pilot initiative, in collaboration with PATH and national PV stakeholders, aimed to strengthen passive safety surveillance through a training and mentoring program of HCPs in healthcare facilities in three SSA countries: Malawi, Côte d'Ivoire, and Democratic Republic of Congo (DRC). Project implementation was country-driven, led by the Ministry of Health via the national PV center or department, and was adapted to each country's needs. The implementation phase for each country was scheduled to last 18 months. At project start, low AE reporting rates reflected that awareness of PV practices was very low among HCPs in all three countries, even if a national PV center already existed. Malawi did not have a functional PV system nor a national PV center prior to the start of the initiative. After 18 months of PV training and mentoring of HCPs, passive safety surveillance was enhanced significantly as shown by the increased number of AE reports: from 22 during 2000-2016 to 228 in 18 months to 511 in 30 months in Malawi, and ~ 80% of AE reports from trained healthcare facilities in Côte d'Ivoire. In DRC, project implementation ended after 7 months because of the SARS-CoV-2 pandemic. Main challenges encountered were delayed AE report transmission (1-2 months, due mainly to remoteness of healthcare facilities and complex procedures for transmitting reports to the national PV center), delayed or no causality assessment due to lack of expertise and/or funding, negative perceptions among HCPs toward AE reporting, and difficulties in engaging public health programs with the centralized AE reporting processes. This pilot project has enabled the countries to train more HCPs, increased reporting of AEs and identified KPIs that could be flexibly replicated in each country. Country ownership and empowerment is essential to sustain these improvements and build a stronger AE reporting culture.

Indexed as

COVID-19PharmacovigilanceHumansMalawiPilot ProjectsSARS-CoV-2Adverse eventsCôte d’IvoireDemocratic Republic of CongoHealthcare professionalsMalawiMentoringPharmacovigilancePilot initiativeSub-Saharan AfricaTraining

Identifiers

PMID35978276
PMCPMC9383683
OpenAlexW4292121757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.